Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6135841 | Microbes and Infection | 2012 | 11 Pages |
Abstract
No commercially live vaccine against cholera caused by Vibrio cholerae O139 serogroup is available and it is currently needed. Virulent O139 strain CRC266 was genetically modified by firstly deleting multiple copies of the filamentous phage CTXÏ, further tagging by insertion of the endoglucanase A coding gene from Clostridium thermocellum into the hemagglutinin/protease gene and finally deleting the mshA gene, just to improve the vaccine biosafety. One of the derived strains designated as TLP01 showed full attenuation and good colonizing capacity in the infant mouse cholera model, as well as highly immunogenic properties in the adult rabbit and rat models. Since TLP01 lacks MSHA fimbriae, it is refractory to infection with another filamentous phage VGJÏ and therefore protected of acquiring CTXÏ from a recombinant hybrid VGJÏ/CTXÏ. This strategy could reduce the possibilities of stable reversion to virulence out of the human gut. Furthermore, this vaccine strain was impaired to produce biofilms under certain culture conditions, which might have implications for the strain survival in natural settings contributing to vaccine biosafety as well. The above results has encouraged us to consider TLP01 as a live attenuated vaccine strain having an adequate performance in animal models, in terms of attenuation and immunogenicity, so that it fulfills the requirements to be evaluated in human volunteers.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Talena Ledón, Beatriz Ferrán, Celso Pérez, Edith Suzarte, Joivier Vichi, Karen Marrero, Reinaldo Oliva, Rafael Fando,